en · de · es
analytical-notes.peptides5388.com › News › Background And Receptor Mechanism — What the Evidence Shows

Background And Receptor Mechanism — What the Evidence Shows

By Editorial Desk · published 2026-06-18 · last reviewed 2026-07-18 · News

A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-07-18. Anything still debated is marked as such rather than presented as settled.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

Background and Mechanism

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

Related pages on this site

Analytical and Handling Considerations

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

Supporting material

It causes similar alterations on EEG readings and sleep architecture as benzodiazepines and causes disturbances in sleep architecture on withdrawal as part of its rebound effect. Zopiclone reduces both delta waves (slow-wave sleep) and the number of high-amplitude delta waves whilst increasing low-amplitude waves. Zopiclone reduces the total amount of time spent in REM sleep as well as delaying its onset. In EEG studies, zopiclone significantly increases the energy of the beta frequency band, increasing stage 2. Zopiclone is less selective to the α1 site and has higher affinity to the α2 site than zaleplon. Zopiclone is therefore very similar pharmacologically to benzodiazepines.

Ian Buruma, author and journalist; board member of Human Rights in China; fellow of European Council of Foreign Relations; journalist for The New York Review of Books and has written for The Guardian; held fellowships at Wissenschaftskolleg and at Woodrow Wilson International Center for Scholars in Washington, D.C.; was Alistair Horne fellow of St Antony's College in Oxford. Stephen Bush; ( b. 1990) columnist and associate editor at the Financial Times; has written for The Guardian, The Daily Telegraph, The Jewish Chronicle, Jewish News, Times of Israel, The i Paper and New Statesman; runner-up in the Young Journalist of the Year awards category in Press Awards; was awarded Political Studies Association's Journalist of the Year award;was appointed to chair the Board of Deputies of British Jews' Commission on Racial Inclusivity in the Jewish Community. Barbara Charone author of authorised biography of Keith Richards; board member of Chelsea F.C.; journalist and music critic for the NME, Rolling Stone, Sounds magazine and Creem; public relations and press director at WEA; founded the agency MBC PR where clients include Madonna, Depeche Mode, Primal Scream, Robert Plant, Pearl Jam, Rod Stewart and Christina Aguilera as well as comedians David Walliams, Graham Norton and Russell Brand; won the Music Week Press Award in 2006 and 2009; The Guardian included her on list of "The 20 most powerful celebrity makers" as "Britain's most powerful music PR", citing her reviving of careers of Madonna and Neil Diamond and establishing Duffy and Mark Ronson. Charone is on Chelsea F.C.

Platelet-rich plasma (PRP), also known as autologous conditioned plasma, is a concentrate of plasma protein derived from whole blood, centrifuged to remove red blood cells but retaining platelets. Though promoted for treating various medical conditions, evidence of its benefits was mixed as of 2020, showing effectiveness in certain conditions and ineffectiveness in others. As a concentrated source of blood plasma and autologous conditioned plasma, PRP contains multiple growth factors and other cytokines that can stimulate the healing of soft tissues and joints. Indications for its use include sports medicine and orthopaedics (such as acute muscle strains, tendinopathy, tendinosis, muscle-fascial injuries, and osteoarthritis) dermatology (for androgenic alopecia, wound healing, and skin rejuvenation), and even proctology (for fistula en ano). Various preparation protocols exist, with the underlying principle of concentrating platelets to 3–5 times physiological levels, then injecting this concentrate into the tissue where healing is desired. Beyond clinical practice, PRP has been utilized in various tissue engineering applications involving bone, cartilage, skin, and soft tissue repair. It serves as a source for the delivery of growth factors and/or cells within tissue-engineered constructs, often in combination with biomaterials.

Sources: en.wikipedia.org

Supporting material

=== Weight loss === Chitosan is marketed in a tablet form as a "fat binder". Although the effect of chitosan on lowering cholesterol and body weight has been evaluated, the effect appears to have no or low clinical importance. Reviews from 2016 and 2008 found there was no significant effect, and no justification for overweight people to use chitosan supplements. In 2015, the U.S. Food and Drug Administration issued a public advisory about supplement retailers who made exaggerated claims concerning the supposed weight loss benefit of various products.

=== Defining agrifood systems resilience === The resilience of agrifood systems builds on the concept of resilience, which originated in the study of ecosystems and evolved over 50 years into an object of study across an array of disciplines, including engineering, agriculture, economics and psychology. Although there is little agreement today as to a precise definition across disciplines, broadly speaking, resilience can be defined as the dynamic capacity to continue to achieve goals despite disturbances. In a call for cross-sectoral collaboration to prevent, anticipate, absorb, adapt and transform in the face of shocks and stresses across all sectors of society, the United Nations has developed and adopted the UN Common Guidance on Helping Build Resilient Societies. Since there is a wide variety of risks relating to understanding resilience, the UN offers the following definition: "the ability of individuals, households, communities, cities, institutions, systems and societies to prevent, anticipate, absorb, adapt, and transform positively, efficiently and effectively when faced with a wide range of risks, while maintaining an acceptable level of functioning and without compromising long-term prospects for sustainable development, peace and security, human rights and well-being for all." Resilience building is a system-wide multi-risk, multi-actor and multisectoral effort.

==== Virulence ==== A field SeV isolate, that is attenuated through egg-passages, is less virulent for mouse respiratory cells. Therefore, the strains that were isolated from animals a few decades ago and went through multiple passages in eggs are less virulent for mice in comparison with the strains that are fresh field isolates.

=== Synthesis === Hydrocodone is most commonly synthesized from thebaine, a constituent of opium latex from the dried poppy plant. Once thebaine is obtained, the reaction undergoes hydrogenation using a palladium catalyst.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

Is SR9009 legal?

Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.

Network